Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma develops novel therapeutics and drug-delivery systems for stress-induced psychiatric disorders, chronic pain and central nervous system diseases, while also disclosing activity in cryptocurrency treasury and AI infrastructure initiatives. Company news frequently centers on SPC-15, an intranasal serotonin 5-HT4 receptor agonist program for PTSD and anxiety, as well as other pipeline work involving psychedelic-derived and traditional therapeutic approaches.
Recurring updates include patent allowances and applications in key jurisdictions, FDA and federal-policy context for psychedelic medicines, clinical-development planning, and new CNS discovery initiatives such as ibogaine-based approaches for traumatic brain injury. Corporate news also covers common-stock repurchase authorization, equity-financed asset purchases, the QwikAgents AI-agent platform, and cryptocurrency-related software assets.
Silo Pharma (Nasdaq: SILO) announced that its wholly owned subsidiary QwikAgents has been accepted into Advanced Micro Devices’ AMD AI Developer Program. According to Silo Pharma, QwikAgents will gain access to AMD Developer Cloud credits, advanced AI tools, training resources and a global developer community to accelerate enterprise AI agent development.
QwikAgents is building a subscription-based AI agent platform, with starter plans from $14 per month, designed for individuals, developers, small businesses and enterprises. The platform targets use cases such as research, content creation, scheduling, coding, browser and workflow automation, and aims to leverage AMD resources for development, hosting, testing, optimization and potential training of AI workloads.
Silo Pharma (Nasdaq: SILO) entered definitive agreements for a private placement of 619,965 common shares (or pre-funded warrants) plus Series A-3 and short-term Series A-4 warrants to purchase up to an additional 1,239,930 shares in total, at $6.452 per share and associated warrants.
The upfront aggregate gross proceeds are expected to be approximately $4 million, before fees, with up to approximately $7.7 million in potential additional gross proceeds if all warrants are exercised in cash at an exercise price of $6.21 per share. The offering, led by H.C. Wainwright & Co. as exclusive placement agent, is expected to close on or about July 10, 2026, subject to customary conditions. According to Silo Pharma, net proceeds will be used for working capital and general corporate purposes, and the securities are being issued in a private placement under Section 4(a)(2) and Regulation D, with resale registration statements to be filed for the unregistered securities.
Silo Pharma (Nasdaq:SILO) announced that its wholly owned subsidiary QwikAgents has joined the NVIDIA Developer Program to support development of its enterprise AI agent integration platform.
QwikAgents aims to use NVIDIA’s AI software ecosystem, frameworks, and training resources to enhance autonomous AI workflows for business customers.
Silo Pharma (Nasdaq: SILO) engaged drug-device partner Resyca to run a robustness study on the microchip-based Soft-Mist nasal spray delivering SPC-15, its lead intranasal prophylactic PTSD treatment.
The 30-day study will test device performance and SPC-15 formulation stability and is expected to support a planned FDA Type C meeting and IND/Phase 1 strategy under a previously aligned 505(b)(2) pathway.
Silo Pharma (Nasdaq:SILO) reported positive stability data for its investigational PTSD prophylactic treatment SPC-15, a soft-mist intranasal formulation. Real-time data over nine months and six-month accelerated testing showed physical, chemical and microbiological stability within predefined specifications, supporting IND-enabling CMC requirements and advancement toward a first-in-human Phase 1 clinical trial.
Silo Pharma (Nasdaq: SILO) announced it has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2) as of June 17, 2026. The stock will continue trading on the Nasdaq Capital Market, and the compliance matter is considered closed.
The company also highlighted confidence in advancing its lead PTSD candidate SPC-15 toward first-in-human trials and progressing its QwikAgents AI agents platform.
Silo Pharma (Nasdaq: SILO) filed a provisional USPTO patent titled “Compositions and Methods for Treating Traumatic Brain Injuries and/or Disorders Associated therewith with Ibogaine.” The company will evaluate ibogaine and related compounds for TBI and associated neuropsychiatric conditions, citing reported structural brain changes and symptom reductions after single treatments. The release notes a projected $6.0 billion global TBI therapeutics market by 2032 and references recent federal actions to accelerate psychedelic drug development.
Silo Pharma (NASDAQ: SILO) welcomed coordinated U.S. federal actions on April 29, 2026 that accelerate psychedelic therapeutic research and regulatory clarity for PTSD and related disorders. Key developments include ARPA-H EVIDENT initial awardees (including Johns Hopkins), FDA issuance of three Commissioner’s National Priority Vouchers, an IND clearance to DemeRx NB, and a promised final guidance on psychedelic drug development to be published imminently.
Silo frames these moves as validating data-driven approaches to complex neurological and psychiatric conditions and says the federal actions could lay groundwork for new PTSD therapies.
Silo Pharma (Nasdaq: SILO) acquired assets of Qwikagents.ai and launched a dedicated AI subsidiary to expand into the AI agent market. The firm cites market projections of $47–$53 billion by 2030 and 43–50% annual growth. Silo also plans to submit an IND for SPC-15 to the FDA and advance its PTSD program into Phase 1 after approval.
The move creates a second business line—AI infrastructure—while retaining focus on clinical development.
Silo Pharma (NASDAQ: SILO) highlighted its lead intranasal PTSD candidate, SPC-15, and said it is positioned to benefit from renewed federal focus on psychedelic-based therapies following an April 18, 2026 executive order directing agencies to accelerate research.
SPC-15 is a 5-HT4 receptor agonist delivered intranasally via a nose-to-brain device, advanced under a 505(b)(2) regulatory pathway, backed by Columbia University-licensed IP, and preparing for IND engagement with the FDA.